The GAAP revenue decline and swing to a net loss are the dominant signals, outweighing the reaffirmed guidance and pipeline metrics. Monitor the Q3 2026 earnings for evidence that the contracted revenue backlog is converting to GAAP revenue and that the operating loss is narrowing. The stock may face continued pressure until the company demonstrates a return to revenue growth and profitability.
Price Chart
Executive Summary
Health In Tech reported Q2 2026 revenue of $8.1M (down 13.5% YoY from $9.3M) and a net loss of $2.5M ($-0.04 EPS), reversing a $0.6M profit in Q2 2025. The EPS missed consensus of $-0.03 by 33%. The company reaffirmed full-year 2026 revenue guidance of $45M-$50M, but the GAAP revenue decline and swing to a loss are the headline negatives. Contracted Revenue of $32.3M and Pipeline Revenue of $66.3M provide forward visibility, but the near-term financial deterioration dominates the read-through.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $8.1M vs $9.3M YoY (-13.5%)
- Net loss of $2.5M ($-0.04 EPS) vs net income of $0.6M ($0.01 EPS) in Q2 2025
- EPS of $-0.04 missed consensus of $-0.03 (-33% surprise)
- Adjusted EBITDA was -$1.3M vs +$1.6M in Q2 2025
- Full-year 2026 revenue guidance reaffirmed at $45M-$50M
- Contracted Revenue $32.3M; Pipeline Revenue $66.3M as of July 31, 2026
- Distribution partners grew 19.9% YoY to 933
Financial Impact
Revenue declined $1.2M YoY; net income swung from +$0.6M to -$2.5M; operating cash flow was -$2.9M in Q2 2026 vs +$1.5M in Q2 2025
Risk Factors
- Revenue decline may persist if contracted revenue conversion slows
- Negative operating cash flow of -$2.9M in Q2 2026 raises liquidity concerns given only $6.5M cash on hand
- Guidance of $45M-$50M implies H2 2026 revenue of $28.2M-$33.2M, requiring a significant acceleration from the $16.8M in H1 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302851136 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.5359 | awaiting T+60 | — | $0.5360 (+0.02%) |
Oct 22, 2026 4d ago | 3 | $0.5623 | awaiting T+60 | — | $0.5360 (−4.68%) |
Oct 16, 2026 10d ago | 8-K | $0.6350 | awaiting T+60 | — | $0.5360 (+15.59%) |
Oct 16, 2026 11d ago | EFFECT | $0.6520 | awaiting T+60 | — | $0.5360 (+17.79%) |
Oct 13, 2026 13d ago | DEF 14A | $0.6780 | awaiting T+60 | — | $0.5360 (+20.94%) |
Oct 9, 2026 17d ago | S-3/A | $0.7200 | awaiting T+60 | — | $0.5360 (+25.56%) |
Sep 30, 2026 26d ago | Press Release | $0.7380 | awaiting T+60 | — | $0.5360 (−27.37%) |
Sep 29, 2026 27d ago | SC 13G | $0.8525 | awaiting T+60 | — | $0.5360 (−37.13%) |
Sep 4, 2026 7w ago | S-3 | $0.9801 | awaiting T+60 | — | $0.5360 (+45.31%) |
Aug 13, 2026 10w ago | Press Release | $1.01 | awaiting T+60 | — | $0.5360 (+46.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers